Obiltoxaximab

From WikiMD.org
Jump to navigation Jump to search

Obiltoxaximab (pronounced oh-bil-tox-ax-i-mab) is a monoclonal antibody designed for the treatment and prevention of inhalational anthrax, a life-threatening illness caused by the bacterium Bacillus anthracis.

Etymology

The name "Obiltoxaximab" is derived from its function. The prefix "Ob-" is designated for products related to the immune system, "ilto-" for the interleukin system, "x-" for a target related to the immune system, "axi-" for a rat/mouse hybrid, and "-mab" for monoclonal antibody.

Usage

Obiltoxaximab is used in conjunction with appropriate antibacterial drugs when alternative therapies are not available or not appropriate. It binds to the protective antigen (PA) component of the anthrax toxin to prevent it from interacting with its cellular receptors, thereby blocking the toxin's harmful effects.

Related Terms

  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
  • Anthrax: A serious disease caused by Bacillus anthracis, a bacterium that forms spores.
  • Bacillus anthracis: The bacterium that causes anthrax.
  • Protective Antigen: One of the three proteins composing the anthrax toxin, it binds to receptors on the host cell and translocates the other two proteins into the cell.

See Also

  • Raxibacumab: Another monoclonal antibody used for the treatment of inhalational anthrax.

References

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski